Tirzepatide vs Semaglutide: A Detailed Head-to-Head

Semaglutide is a GLP-1 receptor agonist—it activates only the GLP-1 receptor. Tirzepatide is a dual GIP/GLP-1 receptor agonist—it activates both GIP and GLP-1 receptors. This mechanistic difference is fundamental and explains why head-to-head efficacy comparisons show tirzepatide superiority for weight loss and glycaemic control.

Both peptides are administered as once-weekly subcutaneous injections. Both activate the same GLP-1 receptor and share similar gastrointestinal side effects. However, tirzepatide's additional GIP activation provides incremental metabolic benefit.

Semaglutide and tirzepatide both activate GLP-1 receptors, producing overlapping effects: enhanced glucose-stimulated insulin secretion, suppression of glucagon release, slowed gastric emptying, and appetite suppression. These shared effects explain why both achieve clinically significant weight loss and glycaemic control. The GLP-1 pathway is the dominant mechanism contributing to both peptides' metabolic benefits.

Semaglutide has been available longer and has more extensive long-term real-world experience and cardiovascular outcome trial data demonstrating reduction in major adverse cardiovascular events. This longer track record provides reassurance regarding semaglutide's long-term safety and efficacy.

Tirzepatide's additional GIP receptor activation distinguishes it from semaglutide. The GIP pathway contributes to enhanced appetite suppression and metabolic regulation beyond what GLP-1 alone achieves. This additional mechanism translates to superior weight loss: tirzepatide achieves approximately 21-22% weight loss at the highest dose, while semaglutide achieves approximately 13-14%.

For type 2 diabetes, tirzepatide achieved HbA1c reduction approximately 0.3-0.4 percentage points greater than semaglutide in head-to-head trials (SURPASS-2). This modest numerical difference is clinically meaningful when targeting specific HbA1c goals.

In weight management (SURMOUNT vs. comparable semaglutide trials), tirzepatide's greater weight loss advantage is most evident. Approximately 85% of tirzepatide recipients achieved at least 5% weight loss compared to approximately 65-70% with semaglutide. Higher weight loss thresholds (15%, 20%) show more pronounced tirzepatide advantage. For individuals prioritising maximum weight loss, tirzepatide's superiority is relevant.

For type 2 diabetes, the differences are more modest. Tirzepatide's slightly superior HbA1c reduction may matter for individuals struggling to achieve target HbA1c with semaglutide. However, both peptides achieve clinically adequate glycaemic control in most individuals. Individual responses vary, and some patients respond better to one agent than the other due to genetic or phenotypic differences.

Tirzepatide was directly compared to semaglutide in SURPASS-2 for type 2 diabetes and indirectly compared in weight management trials (SURMOUNT vs. semaglutide trials). These comparisons demonstrate tirzepatide's superiority but are not head-to-head weight loss trials using identical protocols.

Semaglutide has more extensive cardiovascular outcome trial data (SUSTAIN-6 demonstrated reduction in cardiovascular events). Tirzepatide's cardiovascular outcome trials are ongoing, so definitive comparative cardiovascular safety data are not yet available.

Both tirzepatide and semaglutide are approved in Australia and globally. Mounjaro and Zepbound (tirzepatide) and Ozempic and Wegovy (semaglutide) are all available through regulated pathways. Regulatory approval for both supports their safety and efficacy.

Availability through the PBS and patient cost may differ. Healthcare providers and patients should check current PBS restrictions and patient contributions for each medication in the jurisdiction of use.